Cost-effectiveness analysis of mecapegfilgrastim and recombinant human granulocyte stimulating facto...
Cost-effectiveness analysis of mecapegfilgrastim and recombinant human granulocyte stimulating factor for primary prophylaxis of chemotherapy-induced neutropenia in non-small cell lung cancer
About this item
Full title
Author / Creator
Gu, Yong-Li , Sun, Zeng-Xian , Sun, Ying , Guan, Xin and Jiang, Dao-Li
Publisher
Germany: Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG
Journal title
Language
English
Formats
Publication information
Publisher
Germany: Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG
Subjects
More information
Scope and Contents
Contents
To evaluate the efficacy, safety, and economics of mecapegfilgrastim and recombinant human granulocyte colony-stimulating factor (rhG-CSF) in the primary prevention of chemotherapy-related neutropenia in non-small cell lung cancer (NSCLC).
Data from 181 patients with NSCLC who received intermediate risk chemotherapy were collected from the infor...
Alternative Titles
Full title
Cost-effectiveness analysis of mecapegfilgrastim and recombinant human granulocyte stimulating factor for primary prophylaxis of chemotherapy-induced neutropenia in non-small cell lung cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2918200032
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2918200032
Other Identifiers
ISSN
0946-1965
DOI
10.5414/CP204479
